TUCSON   520.748.4400

Medical Device Entrepreneur and Investor Joins RCT Board


Research Corporation Technologies (RCT) has appointed D. Ronald Yagoda to its board of directors, effective Oct. 1, 2007.

Yagoda has extensive experience in the investment banking and medical device industries.

He was a senior investment officer for employee benefit funds at The Bankers Trust Company in New York. He joined Marcus Schloss and Co. in 1976 and retired in 1988 as executive vice president and director. He was a member of the New York Stock Exchange and the American Stock Exchange.

He founded DryAz Consulting LLC in 1993. The Scottsdale, Ariz., company provides strategic and financial advice to companies primarily in the medical-device area. In 1993, he also founded Orthopaedic Biosystems Ltd (OBL), a medical device company specializing in sports-related injuries. In 2000, Smith & Nephew, a British orthopedic company, purchased OBL.

From 2002 to 2004, Yagoda served as executive director for OsteoBiologics Inc., (OBI) a biomaterials company in San Antonio, Texas, that specializes in regeneration of bone and cartilage. By refocusing its business plan and re-financing the Company, he enabled OBI to commercialize its technology in late 2003. In 2006, Smith and Nephew Endoscopy acquired OsteoBiologics.

Yagoda served on the International Board of Visitors at the Neeley School of Business at Texas Christian University in Fort Worth, Texas. He serves on the Dean’s Advisory Board at the Price College of Business at the University of Oklahoma and is a member of the Bizzell Memorial Library board at OU. He is currently a director for Orthoscan Inc. and Vitruvian Corporation and has served as a director of several medical device companies over the last 30 years. He is a trustee of the Phoenix Art Museum and is actively involved with the Scottsdale Healthcare Foundation.

“We are pleased that Ron accepted our invitation to join the board of directors,” said RCT Chairman Gary Munsinger, Ph.D. “His knowledge and experience in finance and medical device investing will add significant depth to our board.”

“Ron’s background as an entrepreneur and ability to advance technology in the medical field will be valuable to RCT,” said RCT president and chief executive officer Shaun Kirkpatrick. “I welcome him and anticipate working closely with him.”